Compare · DXCM vs RVP
DXCM vs RVP
Side-by-side comparison of DexCom Inc. (DXCM) and Retractable Technologies Inc. (RVP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and RVP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.76B, about 1222.8x RVP ($19.4M).
- Over the past year, DXCM is down 13.5% and RVP is down 10.7% - RVP leads by 2.8 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 2 for RVP).
- DXCM has more recent analyst coverage (25 ratings vs 0 for RVP).
- Company
- DexCom Inc.
- Retractable Technologies Inc.
- Price
- $61.55-1.84%
- $0.65-0.62%
- Market cap
- $23.76B
- $19.4M
- 1M return
- -7.89%
- -8.30%
- 1Y return
- -13.51%
- -10.72%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2005
- 2001
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Retractable Technologies Inc.
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other medical products for the healthcare industry in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holder; allergy tray; IV safety catheter; Patient Safe syringes and Luer Caps; VanishPoint blood collection set; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest RVP
- Retractable Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Retractable Technologies, Inc. Announces Workforce Reduction
- Retractable Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Retractable Technologies, Inc. Reports Results for 2025
- Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders
- SEC Form 10-K filed by Retractable Technologies Inc.
- SEC Form DEFA14A filed by Retractable Technologies Inc.
- SEC Form DEF 14A filed by Retractable Technologies Inc.
- Retractable Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders